白细胞介素-23/白细胞介素-17信号通路在自身炎症性和自身免疫性葡萄膜炎中的激活
本文综述了IL-23/IL-17通路在自身炎症性和自身免疫性葡萄膜炎(如Vogt-小柳原田病、白塞病、脊柱关节炎相关葡萄膜炎、眼结节病、交感性眼炎和鸟枪弹样脉络膜视网膜病变)中的激活证据。遗传和生物标志物数据显示这些疾病共享该通路激活的分子基础,动物模型表明致病性Th17细胞诱导实验性自身免疫性葡萄膜炎,IL-17可靶向视网膜色素上皮细胞并引发下游炎症级联。目前已有多种阻断IL-23/IL-17通路的药物在初步研究中用于葡萄膜炎治疗。
要点
- 多种自身炎症性和自身免疫性葡萄膜炎共享IL-23/IL-17通路激活的分子基础。
- IL-17可靶向视网膜色素上皮细胞,引发炎症级联并可能影响视网膜屏障功能。
- 阻断IL-23/IL-17通路的药物已在初步研究中评估用于葡萄膜炎治疗。
核心结论
- IL-23/IL-17通路的激活是自身炎症性和自身免疫性葡萄膜炎的关键生物学事件,可作为重要治疗靶点。
研究设计与样本
- 本文为综述,总结IL-23/IL-17通路在自身炎症性和自身免疫性葡萄膜炎中的生物学知识和初步临床数据。
主要发现
- 遗传和生物标志物数据提示Vogt-小柳原田病、白塞病、脊柱关节炎相关葡萄膜炎、眼结节病、交感性眼炎和鸟枪弹样脉络膜视网膜病变共享IL-23/IL-17通路激活。
- 多种因素包括遗传易感性、细胞因子失衡、感染因子和肠道改变可触发该通路异常应答。
- IL-23/IL-17通路活性增强促进Th17细胞的扩增和致病性。
- 动物模型证据表明致病性Th17细胞的发展诱导实验性自身免疫性葡萄膜炎。
- 视网膜色素上皮细胞可能是IL-17的靶细胞,IL-17触发下游炎症级联并导致其功能障碍,可能影响视网膜屏障功能。
临床怎么用
- IL-23/IL-17通路可作为自身炎症性和自身免疫性葡萄膜炎的潜在治疗靶点。
- 已有多种阻断IL-23/IL-17通路的药物在初步研究中用于葡萄膜炎治疗评估。
- 未来研究可聚焦于靶向IL-23/IL-17通路的转化医学以改善葡萄膜炎的诊断和治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Uveitis is a group of diseases characterized by intraocular inflammation, of which some are driven by autoinflammatory or autoimmune responses, such as Vogt-Koyanagi-Harada disease, Behçet's disease, uveitis associated with spondyloarthritis, ocular sarcoidosis, sympathetic ophthalmia and birdshot chorioretinopathy. These entities have various clinical forms, but genetic and biomarker data suggest that they share a common molecular basis, activation of the Interleukin (IL)-23/IL-17 pathway. Multiple factors including genetic predisposition, various cytokine imbalances, infectious agents and gut alterations are found to trigger an aberrant response of this pathway. The enhanced activity of the IL-23/IL-17 pathway is committed to the expansion and pathogenicity of Th17 cells. Evidence from animal models demonstrates that the development of pathogenic Th17 cells is responsible for the induction of experimental autoimmune uveitis. Further findings indicate that retinal pigment epithelium (RPE) cells may be a target of IL-17. IL-17 triggers downstream inflammatory cascades and causes dysfunction of RPE cells, which may affect retinal barrier function and thereby promote intraocular inflammation. Currently, several emerging drugs blocking the IL-23/IL-17 pathway have been assessed for the treatment of uveitis in pilot studies. The purpose of this is to summarize updated biological knowledge and preliminary clinical data, providing the rationale for further development and evaluation of novel drugs targeting the IL-23/IL-17 pathway in autoinflammatory and autoimmune uveitis. Future studies may focus on translational medicine targeting the IL-23/IL-17 pathway for the improvement of diagnosis and treatment of uveitis. In conclusion, activation of the IL-23/IL-17 pathway is a critical biological event and can be an important target for the treatment of autoinflammatory and autoimmune uveitis.
引用
- Zhong Z, Su G, Kijlstra A, et al. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2020. PMID: 32422390. doi:10.1016/j.preteyeres.2020.100866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。